Franco Granella
Overview
Explore the profile of Franco Granella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
1738
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Landi D, Bartolomeo S, Bovis F, Amato M, Bonavita S, Borriello G, et al.
Mult Scler
. 2024 Sep;
30(11-12):1503-1513.
PMID: 39263885
Background: Evidence on the impact of dimethyl fumarate (DMF) during pregnancy in women with multiple sclerosis (MS) is limited. Objectives: To investigate disease activity and pregnancy outcomes in a retrospective...
2.
Portaccio E, Betti M, de Meo E, Addazio I, Pasto L, Razzolini L, et al.
J Neurol
. 2024 Sep;
271(10):7066-7068.
PMID: 39231861
No abstract available.
3.
Simone M, Lucisano G, Guerra T, Paolicelli D, Rocca M, Morra V, et al.
J Neurol
. 2024 Aug;
271(10):6782-6790.
PMID: 39179712
Background: To compare Expanded Disability Status Scale (EDSS) trajectories over time between Multiple Sclerosis (MS) groups with pediatric (POMS), adult (AOMS) and late (LOMS) onset, and between patients with and...
4.
Iaffaldano P, Lucisano G, Guerra T, Paolicelli D, Portaccio E, Inglese M, et al.
Ann Clin Transl Neurol
. 2024 Jul;
11(8):2008-2015.
PMID: 38970214
Objective: No direct comparisons of the effect of natalizumab and ocrelizumab on progression independent of relapse activity (PIRA) and relapse-associated worsening (RAW) events are currently available. We aimed to compare...
5.
Portaccio E, Betti M, de Meo E, Addazio I, Pasto L, Razzolini L, et al.
J Neurol
. 2024 May;
271(8):5074-5082.
PMID: 38805052
Objectives: We investigated the occurrence and relative contribution of relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA) to confirmed disability accrual (CDA) and transition to secondary progression (SP)...
6.
Chisari C, Aguglia U, Amato M, Bergamaschi R, Bertolotto A, Bonavita S, et al.
Neurotherapeutics
. 2024 May;
21(4):e00363.
PMID: 38714462
Treatment options for secondary progressive MS (SPMS) are limited, especially considering that the new drugs recently approved are licensed for actively relapsing patients. We aimed to compare the disability progression...
7.
Bianchi A, Matranga D, Patti F, Maniscalco L, Pilotto S, Di Filippo M, et al.
J Neurol
. 2024 Feb;
271(5):2182-2194.
PMID: 38366072
Objective: Multiple sclerosis (MS) is a complex disorder in which environmental and genetic factors interact modifying disease risk and course. This multicentre, case-control study involving 18 Italian MS Centres investigated...
8.
Iaffaldano P, Lucisano G, Guerra T, Patti F, Cocco E, De Luca G, et al.
J Neurol
. 2023 Dec;
271(3):1150-1159.
PMID: 38135850
Background: Active relapsing-remitting (RR) and secondary progressive (SP) multiple sclerosis (MS) are currently defined as "relapsing MS" (RMS). The aim of this cross-sectional study was to assess drivers of treatment...
9.
Iaffaldano P, Portaccio E, Lucisano G, Simone M, Manni A, Guerra T, et al.
JAMA Neurol
. 2023 Nov;
81(1):50-58.
PMID: 38010712
Importance: Although up to 20% of patients with multiple sclerosis (MS) experience onset before 18 years of age, it has been suggested that people with pediatric-onset MS (POMS) are protected...
10.
Bisecco A, Matrone F, Capobianco M, De Luca G, Filippi M, Granella F, et al.
J Neurol
. 2023 Nov;
271(2):699-710.
PMID: 37982852
Introduction: During the COVID-19 pandemic, ocrelizumab (OCR) infusions for MS patients were often re-scheduled because of MS center's disruption and concerns regarding immunosuppression. The aim of the present study was...